China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in its Phase I ERASER study. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ATG-017 in combination with nivolumab for the treatment of advanced solid tumors. The trial is conducted across the US and Australia, with the monotherapy segment taking place in Australia and the combination segment occurring simultaneously in both the US and Australia.
ATG-017: A Potent and Selective ERK1/2 Inhibitor
ATG-017 is an oral, potent, and selective small-molecule inhibitor of the extracellular signal-regulated kinases 1 and 2 (ERK1/2). Antengene holds global development, commercialization, and manufacturing rights for ATG-017. In late 2021, the company entered into a clinical partnership with US-based Bristol-Myers Squibb (BMS, NYSE: BMY) to assess the combination of ATG-017 with the PD-1 inhibitor nivolumab.
Clinical Partnership with Bristol Myers Squibb
Under the terms of the clinical partnership, Antengene is responsible for conducting the clinical trials, while BMS provides nivolumab as required. This collaboration aims to explore the potential synergistic effects of combining ATG-017 with nivolumab, a checkpoint inhibitor, to enhance treatment outcomes for patients with advanced solid tumors.-Fineline Info & Tech
